IL285197A - Methods and preparations for the treatment of sleep apnea - Google Patents

Methods and preparations for the treatment of sleep apnea

Info

Publication number
IL285197A
IL285197A IL285197A IL28519721A IL285197A IL 285197 A IL285197 A IL 285197A IL 285197 A IL285197 A IL 285197A IL 28519721 A IL28519721 A IL 28519721A IL 285197 A IL285197 A IL 285197A
Authority
IL
Israel
Prior art keywords
compositions
methods
sleep apnea
treating sleep
treating
Prior art date
Application number
IL285197A
Other languages
English (en)
Hebrew (he)
Original Assignee
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital Inc filed Critical Brigham & Womens Hospital Inc
Publication of IL285197A publication Critical patent/IL285197A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL285197A 2019-02-08 2021-07-28 Methods and preparations for the treatment of sleep apnea IL285197A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962803223P 2019-02-08 2019-02-08
PCT/US2020/017323 WO2020163785A1 (en) 2019-02-08 2020-02-07 Methods and compositions for treating sleep apnea

Publications (1)

Publication Number Publication Date
IL285197A true IL285197A (en) 2021-09-30

Family

ID=71947080

Family Applications (1)

Application Number Title Priority Date Filing Date
IL285197A IL285197A (en) 2019-02-08 2021-07-28 Methods and preparations for the treatment of sleep apnea

Country Status (17)

Country Link
US (2) US12558327B2 (enExample)
EP (2) EP4635514A3 (enExample)
JP (2) JP7705348B2 (enExample)
KR (2) KR102980795B1 (enExample)
CN (2) CN118557736A (enExample)
AU (2) AU2020219809B2 (enExample)
BR (1) BR112021015600A2 (enExample)
CA (1) CA3129270A1 (enExample)
EA (1) EA202192202A1 (enExample)
ES (1) ES3049086T3 (enExample)
IL (1) IL285197A (enExample)
MX (2) MX2021009407A (enExample)
MY (1) MY210043A (enExample)
PH (1) PH12021551850A1 (enExample)
SG (1) SG11202108225QA (enExample)
UA (1) UA130366C2 (enExample)
WO (1) WO2020163785A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111670050A (zh) 2018-01-30 2020-09-15 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的方法和组合物
ES3049086T3 (en) 2019-02-08 2025-12-12 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
IL307186A (en) * 2021-03-24 2023-11-01 Apnimed Inc Delaware Methods and preparations for treating sleep apnea
JP2024523876A (ja) * 2021-06-17 2024-07-02 アプニメッド,インコーポレイテッド(デラウェア) 睡眠時無呼吸を治療するためのノルエピネフリン再取り込み阻害剤
EP4522149A1 (en) * 2022-05-13 2025-03-19 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
CN119789855A (zh) * 2022-09-02 2025-04-08 爱普宁公司(特拉华) 治疗睡眠呼吸暂停的方法和组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU767877B2 (en) 1999-05-20 2003-11-27 Sepracor, Inc. Methods for treatment of asthma using S-oxybutynin
WO2001062236A2 (en) 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
WO2002089843A1 (en) 2001-03-13 2002-11-14 Millenium Pharmaceuticals, Inc. Methods for treating or preventing cardiovascular disorders by modulating metalloprotease function
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US20040235925A1 (en) 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
CA2566154A1 (en) 2004-05-27 2005-12-08 Warner-Lambert Company Llc Combination of atomoxetine and a 5t1a receptor agonist for treating adhd and other disorders
WO2006023703A2 (en) 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
JP2008524332A (ja) 2004-12-20 2008-07-10 コレジウム ファーマシューティカル, インク. 睡眠傷害のための医薬組成物
FR2889811B1 (fr) * 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
DK2083811T3 (en) 2006-11-22 2017-01-30 Clinical Res Ass Llc PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM
WO2008122019A1 (en) 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
AU2008236624A1 (en) * 2007-04-09 2008-10-16 Sepracor Inc. Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep-related breathing disorders
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
BRPI0821761A2 (pt) * 2007-12-21 2015-06-16 Eurand Inc Composições de comprimidos de desintegração oral de temazepam
US20100204058A1 (en) 2009-01-28 2010-08-12 Howard Yuan-Hao Chang Profiling for Determination of Response to Treatment for Inflammatory Disease
CN107007602A (zh) 2011-01-28 2017-08-04 辉达斯医学研究所 治疗阻塞性睡眠呼吸暂停的方法
TWI621434B (zh) 2014-10-24 2018-04-21 朗齊生物醫學股份有限公司 千憂解藥物應用於癌症治療
HUE047169T2 (hu) 2015-04-27 2020-04-28 Arena Pharm Inc 5-HT2C receptor agonisták és készítmények és felhasználási eljárások
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
ES2925951T3 (es) * 2015-07-22 2022-10-20 John Hsu Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
CN119185558A (zh) 2017-04-28 2024-12-27 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物
CN111670050A (zh) 2018-01-30 2020-09-15 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的方法和组合物
ES3049086T3 (en) 2019-02-08 2025-12-12 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea

Also Published As

Publication number Publication date
CN118557736A (zh) 2024-08-30
CN113692277B (zh) 2024-07-16
MX2021009407A (es) 2021-09-10
ES3049086T3 (en) 2025-12-12
SG11202108225QA (en) 2021-08-30
PH12021551850A1 (en) 2022-05-11
EP3920898A4 (en) 2022-11-09
KR102980795B1 (ko) 2026-06-23
AU2020219809B2 (en) 2025-04-17
WO2020163785A1 (en) 2020-08-13
BR112021015600A2 (pt) 2021-10-05
US12558327B2 (en) 2026-02-24
JP2025084754A (ja) 2025-06-03
EP3920898C0 (en) 2025-09-10
EP4635514A2 (en) 2025-10-22
UA130366C2 (uk) 2026-02-04
KR20210125507A (ko) 2021-10-18
EP4635514A3 (en) 2025-12-24
JP7705348B2 (ja) 2025-07-09
CN113692277A (zh) 2021-11-23
EA202192202A1 (ru) 2021-11-03
EP3920898B1 (en) 2025-09-10
US20220096401A1 (en) 2022-03-31
KR20260103155A (ko) 2026-07-02
AU2025205464A1 (en) 2025-07-31
US20260151361A1 (en) 2026-06-04
EP3920898A1 (en) 2021-12-15
MY210043A (en) 2025-08-22
AU2020219809A1 (en) 2021-08-19
JP2022519721A (ja) 2022-03-24
MX2025004365A (es) 2025-05-02
CA3129270A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
ZA201907158B (en) Methods and compositions for treating sleep apnea
IL276247A (en) Methods and materials for the treatment of sleep apnea
SG11202104158SA (en) Composition and method for treating the lungs
ZA202207394B (en) Compositions and methods for treating hemoglobinopathies
IL271503A (en) Preparations and treatments for sleep disorders
PL3253443T3 (pl) Urządzenie do leczenia chrapania i bezdechu sennego
SG11202013239RA (en) Composition and method for treating pain
IL285886A (en) Preparations and methods for the treatment of laminopathy
IL290348B1 (en) Compositions and methods for surface treatment
IL285796A (en) Methods and preparations for the treatment of cancer
IL280413A (en) Bismuth-thiol preparations and wound treatment methods
SMT202500382T1 (it) Composizioni per trattare e/o prevenire malattie da aggregazione proteica
SG11202102442WA (en) Methods and compositions for preventing and treating atherosclerosis and related diseases
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
EP3589344A4 (en) SOUND ATTENUATION STRUCTURES AND METHODS FOR USE IN THE TREATMENT OF OBSTRUCTIVE SLEEP APNEA
IL304771A (en) Preparations and methods for the treatment of a disease associated with dux4 overexpression
EP3624808A4 (en) PROCEDURES AND COMPOSITIONS FOR IMPROVED SLEEP
IL288440A (en) Materials and methods for the treatment of retinopathy
EP3720351A4 (en) METHODS AND SYSTEMS FOR THE TREATMENT OF SLEEP APNEA
IL307186A (en) Methods and preparations for treating sleep apnea
HK40059516A (en) Methods and compositions for treating sleep apnea
HK40041686A (en) Compositions and methods for treating obstructive sleep apnea
HK40017009A (en) Methods and compositions for treating sleep apnea
HK40112418A (en) Methods and compositions for treating sleep apnea
HK40108218A (en) Methods and compositions for treating sleep apnea